Tenaya Therapeutics, Inc.
TNYA Nasdaq
SEC CIK 1858848
Follow Tenaya Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.7M
Net income
−$18.9M
+6.6% vs same quarter last year
EPS, diluted
−$0.08
+33.3% vs same quarter last year
Operating cash flow
−$17.7M
−13.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$90.6M |
| FY24 | −$111.1M |
| FY23 | −$124.1M |
| FY22 | −$123.7M |
| FY21 | −$72.7M |
| FY20 | −$38.4M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$68.9M |
| FY24 | −$91.5M |
| FY23 | −$103.3M |
| FY22 | −$125.1M |
| FY21 | −$85.9M |
| FY20 | −$45.2M |
| FY19 | - |